Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2009

Novotech and ETI Ally to Harness Indian Clinical Research Opportunities

  • Australia-based CRO, Novotech, and Indian CRO, ETI Klinical, are teaming up to help meet the growing international demand for clinical research in India.

    The joint venture aims to cover a wide range of therapeutic areas including oncology, respiratory disorders, infectious diseases, psychiatry, metabolic disorders, devices, and vaccines. The firms will also offer flexible data management capabilities including Oracle Clinical and SAS as well as Novotech’s Clintrial.

    Novotech’s Asian services were launched in 2007. This collaboration helps exploit what Novotech CEO, Alek Safarian, calls huge opportunities in the growing Indian clinical research sector. “We approached Novotech because of its proven reputation in the region, its focus on Australasia, and its global development reach and client network,” adds Karle Group CEO, Mahendra Karle.

    By taking advantage of ETI’s extensive reach across India, the partners say that clients will have access to 92 trial-ready sites with proven recruitment capabilities and compliance, equating to over 5 million patients, 13,000 beds, and 760 investigators with a cumulative experience of 5,000 years.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »